SJS Investment Consulting
ATYR icon

SJS Investment Consulting’s aTyr Pharma ATYR Stock Holding History

SJS Investment Consulting’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$33 Sell
3
-2
-40% -$39 ﹤0.01% 3146
2026
Q2 		$125 Buy
5
+4
+400% +$105 ﹤0.01% 2564
2026
Q1 		$33 Buy
+1
New +$34 ﹤0.01% 2310

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return
Kingswood Wealth Advisors
Kingswood Wealth Advisors San Diego, California $2.6B AUM 27.46% 1-Year Est. Return

SJS Investment Consulting's ATYR Position: Q3 2026 in Review

SJS Investment Consulting reduced its aTyr Pharma (ATYR) stake by 40% in Q3 2026, selling an estimated $39 and leaving 3 shares worth $33. The position accounts for ﹤0.01% of the portfolio, ranked #3146.

SJS Investment Consulting first reported a position in ATYR in Q1 2026 and has held it in 3 quarters since. The position peaked at $125 in Q2 2026. 31 funds tracked by Wall St. Rank hold ATYR as of Q3 2026.

  • SJS Investment Consulting held 3 shares of aTyr Pharma worth $33 as of Q3 2026.
  • SJS Investment Consulting sold 2 aTyr Pharma shares in Q3 2026, an estimated $39.
  • aTyr Pharma made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #3146 holding.
  • SJS Investment Consulting first reported a position in aTyr Pharma in Q1 2026 and has held it in 3 quarters since.
  • SJS Investment Consulting's aTyr Pharma position peaked at $125 in Q2 2026.
  • 31 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.